2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1859

Meeting the Needs of Rheumatology Health Professional Learners: the Success of the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Online Educational Products
Abstract Number: 670

Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Abstract Number: 998

Mental Health in Patients with Axial Spondyloarthritis: Increasing Our Understanding of the Disease. Results from the Spanish Atlas
Abstract Number: 1884

Mepolizumab for the Treatment of Patients with Eosinophilic Granulomatosis with Polyangiitis: Post-Hoc Results of a Phase III Randomized, Placebo-Controlled Trial
Abstract Number: 2616

Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
Abstract Number: 284

Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease
Abstract Number: 2178

Metabolic Osteoarthritis: Relation of Cardiovascular Disease and Diabetes to Knee Osteoarthritis
Abstract Number: 1724

Metabolic Regulation of Fibrosis in Systemic Sclerosis: The CD38-NAD+ Link
Abstract Number: 2180

Metabolic Syndrome Does Not Modify the Association between Obesity and Hip Osteoarthritis
Abstract Number: 2189

Metabolic Syndrome Influences the Radiographic Progression of Knee Osteoarthritis and Condition the Risk of Erosive Hand OA
Abstract Number: 2521

Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Abstract Number: 2522

Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study
Abstract Number: 15

Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Abstract Number: 1406

Methods for Generating Multiple High-Dimensional Analyses of Cryopreserved Synovial Tissue Developed By the Accelerating Medicines Partnership RA/SLE Network
Abstract Number: 2295

Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].